Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 2Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1

Interventions

Cisplatin 127Carboplatin 127Drug Therapy 116Capecitabine 101Bevacizumab 101Oxaliplatin 99Radiotherapy 97tislelizumab 87Paclitaxel 87Cyclophosphamide 87Gemcitabine 86Specimen Handling 79pembrolizumab 77toripalimab 70Magnetic Resonance Spectroscopy 66Injections 65Fluorouracil 63sintilimab 58Surgical Procedures, Operative 58anlotinib 55Docetaxel 53130-nm albumin-bound paclitaxel 51fludarabine 47Pemetrexed 46Standard of Care 45Immune Checkpoint Inhibitors 45Leucovorin 43Blood Specimen Collection 43Biopsy 43venetoclax 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × BEBT-908 × Clear all
NCT07301138 2025-12-24

BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients

Ruijin Hospital

Phase 2 Not yet recruiting
23 enrolled
LymphoidOther hematologic neoplasm

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡